By Bree Valensin, DVM
As equine veterinarians, we are often faced with navigating an overwhelming marketplace of biologics, supplements, and adjunctive therapies, each with varying levels of efficacy and practicality. In an industry saturated with countless products promising specialized benefits, finding something that genuinely delivers across multiple disciplines of care is rare.
RenoVō® has become one of those tools in my practice.
While many regenerative products are traditionally associated with soft tissue injury or joint maintenance alone, I have found RenoVō® demonstrates clinical utility far beyond those conventional applications. I have incorporated it into a wide range of therapeutic protocols, including ophthalmic support, nebulization therapy, and intravenous administration aimed at promoting overall systemic wellness and recovery. Having a single therapeutic option that is both accessible and adaptable across so many areas of care has proven truly invaluable.
What distinguishes RenoVō® most is its ability to integrate the most beneficial qualities of numerous regenerative and supportive therapies into one refined product. It simplifies that landscape without compromising clinical performance. Throughout my experience utilizing it in practice, I have observed meaningful improvements not only in recovery and athletic longevity, but also in the overall vitality and long-term health of my equine patients.
Perhaps most significantly, RenoVō® has proven especially valuable in the management of aging horses and those affected by metabolic conditions where corticosteroid use may be limited or contraindicated altogether. These patients often require a far more nuanced and conscientious treatment strategy. Having a therapy that supports healing, comfort, and physiologic resilience without heavy reliance on steroids has been extraordinarily beneficial. Witnessing these horses maintain soundness, comfort, and quality of life well into their later years has been deeply rewarding.
To me, RenoVō® represents far more than a therapeutic product. It is an investment in the longevity, wellness, and sustained performance of the horses entrusted to our care.
About the Author
Bree Valensin, DVM is an equine veterinarian based in Weatherford, Texas and founder of Valensin Equine. She earned her veterinary degree from Midwestern University in Phoenix and brings extensive experience working with performance horses. She has incorporated RenoVō® into her therapeutic protocols at her discretion across a wide range of equine cases.
RenoVō® is a liquid, acellular, equine amniotic tissue allograft comprised of amnion and amniotic fluid, intended to supplement and protect tissues. Clinical decisions regarding its use are made at the discretion of the attending veterinarian.
Case presentation: September 8, 2020: A 10-Year-Old Gelding presented to Milestone Veterinary Care, Backus, MN, with a conjunctival squamous cell carcinoma at the lateral canthus causing visual impairment and destruction of the eye. The attending veterinarian, Fonda Lewis Melby, DVM, debulked the mass and began ophthalmic therapy.
October 20, 2020: After six weeks, the mass began to return. The mass was debulked again. At the discretion of the veterinarian, a subconjunctival implant of 1.0 cc RenoVō® was placed near the lesion.
November 24, 2020: Five weeks following the RenoVō® implantation, the lesion improved with no evidence of the mass returning. 
On January 24, 2021: , 3 Months following the RenoVō ® implantation, the eye and conjunctival tissue looked healthy and normal at examination with no sign of squamous cell carcinoma present.
